Bone Growth Stimulators: Electrical (Invasive), Ultrasound - (0084) | CIGNA Coverage Update

Summary: Cigna Healthcare modified its bone growth stimulator coverage policy (policy 0084) effective May 16, 2026. Here's what billing teams need to know before that date.

Cigna Healthcare updated its coverage position criteria for electrical (invasive) and ultrasound bone growth stimulators under policy 0084. This policy governs whether these devices meet medical necessity standards for reimbursement across Cigna commercial plans. The policy does not publish specific CPT or HCPCS codes in the version captured here — we'll cover what that means for your billing process below.

Cigna Bone Growth Stimulator Coverage Criteria and Medical Necessity Requirements 2026

The Cigna bone growth stimulator coverage policy under 0084 covers two distinct device categories: electrical invasive stimulators and ultrasound stimulators. These are not interchangeable under the policy. Your documentation must clearly identify which type the ordering provider is prescribing — and why.

Bone growth stimulators are durable medical equipment. Cigna treats them as such, which means medical necessity documentation carries real weight in the claims review process. A claim denial on one of these devices typically traces back to missing clinical justification, not a coding error.

For electrical invasive stimulators, coverage historically hinges on failed fracture healing. The standard threshold is a fracture that has not shown radiographic evidence of healing after a defined period — typically three to six months of conservative management. The ordering provider needs to document that threshold clearly in the medical record.

Ultrasound bone growth stimulators face a higher bar in most commercial policies. Cigna has historically distinguished between fresh fractures and established nonunions, covering ultrasound stimulators in a narrower set of circumstances. If your practice bills ultrasound bone growth stimulator claims to Cigna, the 2026 modification to policy 0084 is worth a close review against your current documentation templates.

Prior authorization requirements apply to bone growth stimulators under most Cigna commercial plans. Do not assume the plan-level PA requirement is unchanged just because the device type is the same. When a coverage policy is modified, PA criteria often shift alongside it. Confirm the prior auth requirements for each plan your patients carry before May 16, 2026.

The real issue here is that "bone growth stimulator billing" sits in a category where Cigna's clinical review team pays close attention. These are high-cost durable medical equipment items. Cigna will scrutinize the medical necessity criteria on every claim, and a modified policy means the reviewers may be working from updated criteria your team hasn't seen yet.

Cigna Bone Growth Stimulator Exclusions and Non-Covered Indications

Cigna's 0084 policy has historically excluded several indications from coverage. These exclusions apply regardless of what the ordering provider documents — the clinical scenario simply falls outside what Cigna considers covered.

Electrical invasive stimulators are generally not covered for acute fractures. Coverage is reserved for fractures that have failed to heal through conventional treatment. Billing an invasive stimulator for an acute fracture will result in a claim denial under the coverage policy.

Ultrasound stimulators used as a first-line treatment — before conservative care has been attempted — are typically excluded. Cigna does not cover them as a substitute for standard fracture management. They must be positioned in the record as a treatment for a healing problem that has already declared itself.

Both device types are generally considered experimental or not medically necessary for certain spinal applications outside specific, well-documented indications. If your practice has spine surgeons ordering bone growth stimulators for indications outside long bone nonunions or failed spinal fusions, review those cases carefully against the updated policy 0084 before May 16, 2026.

If you're unsure whether a specific clinical scenario falls inside or outside Cigna's updated coverage position, loop in your compliance officer before submitting the claim. The financial exposure on durable medical equipment denials is significant, and a retroactive review of a high-volume bone growth stimulator practice is not a situation you want to explain to a payer's audit team.

Coverage Indications at a Glance

The policy document captured here does not include a granular indication-by-indication breakdown with specific codes attached. The table below reflects the general coverage framework Cigna applies under policy 0084, based on the device categories named in the policy title and Cigna's established coverage position criteria for this policy.

Confirm each indication against the current policy 0084 text directly. Coverage can vary by Cigna plan type — individual, employer-sponsored, and managed care plans may have different criteria applied on top of the base coverage policy.

Cigna Bone Growth Stimulator Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Bone Growth Stimulators Under Cigna Policy 0084

The policy data captured for this modification does not include specific CPT, HCPCS, or ICD-10 codes. Cigna's coverage position criteria documents sometimes reference codes in appendices or supplemental coverage determination documents that are updated separately from the main policy text.

This is a real operational problem for billing teams. You cannot update your charge capture or prior auth workflows without knowing which codes Cigna is applying the updated criteria to.

Here's what to do. First, access the full policy 0084 document directly through the Cigna provider portal or the source link associated with this policy. Look for any attached code lists, billing guidelines supplements, or linked local coverage determination equivalents. Second, check your Cigna provider contract or reach out to your Cigna provider relations representative to confirm which HCPCS codes — typically in the E-code range for durable medical equipment — are being reviewed under the updated criteria. Third, cross-reference against the fee schedule for any reimbursement rate changes tied to the modification.

Do not assume the codes haven't changed just because the policy text hasn't published them here. A coverage policy modification without a code list update is actually common — the clinical criteria change, and the codes follow later. Build your verification process around that reality.

If your team bills high volume for bone growth stimulators to Cigna and you cannot identify the specific codes affected by this modification, that is a situation for your compliance officer and your billing consultant to resolve before May 16, 2026. The financial exposure is too significant to guess.